Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 2746 AL 2760

Crosstalk between epigenetics and mTOR as a gateway to new insights in pathophysiology and treatment of Alzheimer's disease

Agarwal D, Kumari R, Ilyas A, Tyagi S, Kumar R, Poddar NK.

Int J Biol Macromol. 2021 Dec 1;192:895-903. doi: 10.1016/j.ijbiomac.2021.10.026. Epub 2021 Oct 15.

Current research status of blood biomarkers in Alzheimer's disease: Diagnosis and prognosis

Feng L, Li J, Zhang R.

Ageing Res Rev. 2021 Dec;72:101492. doi: 10.1016/j.arr.2021.101492. Epub 2021 Oct 19.

Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: a systematic review

Jeremic D, Jiménez-Díaz L, Navarro-López JD.

Ageing Res Rev. 2021 Dec;72:101496. doi: 10.1016/j.arr.2021.101496. Epub 2021 Oct 21.

The prognostic utility of CSF neurogranin in predicting future cognitive decline in the Alzheimer's disease continuum: A systematic review and meta-analysis with narrative synthesis

Yoong SQ, Lu J, Xing H, Gyanwali B, Tan YQ, Wu XV.

Ageing Res Rev. 2021 Dec;72:101491. doi: 10.1016/j.arr.2021.101491. Epub 2021 Oct 21.

Omega-3 fatty acids and blood-based biomarkers in Alzheimer's disease and mild cognitive impairment: A randomized placebo-controlled trial

Lin PY, Cheng C, Satyanarayanan SK, Chiu LT, Chien YC, Chuu CP, Lan TH, Su KP.

Brain Behav Immun. 2022 Jan;99:289-298. doi: 10.1016/j.bbi.2021.10.014. Epub 2021 Oct 29.

Current progress in aptamer-based sensing tools for ultra-low level monitoring of Alzheimer's disease biomarkers

Zamanian J, Khoshbin Z, Abnous K, Taghdisi SM, Hosseinzadeh H, Danesh NM.

Biosens Bioelectron. 2022 Feb 1;197:113789. doi: 10.1016/j.bios.2021.113789. Epub 2021 Nov 14.

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation

Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, van der Flier WM, Mielke MM, Del Campo M.

Lancet Neurol. 2022 Jan;21(1):66-77. doi: 10.1016/S1474-4422(21)00361-6. Epub 2021 Nov 24.

Blood-based biomarkers of agitation in Alzheimer's disease: Advances and future prospects

Tumati S, Herrmann N, Marotta G, Li A, Lanctôt KL.

Neurochem Int. 2022 Jan;152:105250. doi: 10.1016/j.neuint.2021.105250. Epub 2021 Dec 2.

Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence

Gleason CE, Zuelsdorff M, Gooding DC, Kind AJH, Johnson AL, James TT, Lambrou NH, Wyman MF, Ketchum FB, Gee A, Johnson SC, Bendlin BB, Zetterberg H.

Alzheimers Dement. 2022 Aug;18(8):1545-1564. doi: 10.1002/alz.12511. Epub 2021 Dec 6.

miRNAs as Therapeutic Tools in Alzheimer's Disease

Lee CY, Ryu IS, Ryu JH, Cho HJ.

Int J Mol Sci. 2021 Dec 1;22(23):13012. doi: 10.3390/ijms222313012.

Biomarkers used in Alzheimer's disease diagnosis, treatment, and prevention

Mahaman YAR, Embaye KS, Huang F, Li L, Zhu F, Wang JZ, Liu R, Feng J, Wang X.

Ageing Res Rev. 2022 Feb;74:101544. doi: 10.1016/j.arr.2021.101544. Epub 2021 Dec 18.

Molecular Aspects of Cellular Dysfunction in Alzheimer's Disease: The Need for a Holistic View of the Early Pathogenesis

Merlo S, Spampinato SF, Lim D.

Biomolecules. 2021 Dec 1;11(12):1807. doi: 10.3390/biom11121807.

Tacrine-Natural-Product Hybrids for Alzheimer's Disease Therapy

Oset-Gasque MJ, Marco-Contelles JL.

Curr Med Chem. 2020;27(26):4392-4400. doi: 10.2174/0929867325666180403151725.

Primary Endpoints in Current Phase II/III Trials for Alzheimer Disease: A Systematic Survey of Trials Registered at ClinicalTrials.gov

Takeshima N, Ishiwata K, Sozu T, Furukawa TA.

Alzheimer Dis Assoc Disord. 2020 Jan-Mar;34(1):97-100. doi: 10.1097/WAD.0000000000000297.

Time for Well-Powered Controlled Prospective Studies to Test a Causal Role for Herpes Viruses in Alzheimer's Disease Using Antiherpetic Drugs

Goldschmidt-Clermont PJ, Volinsky FG, LaRosa SP, Gilbert JR, Periçak-Vance MA.

J Gerontol A Biol Sci Med Sci. 2020 May 22;75(6):1058-1060. doi: 10.1093/gerona/glz150.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias